Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline
Retrieved on:
Thursday, September 16, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, Nutrient, Standard of care, Cosford, Precision medicine, Program, Idiopathic pulmonary fibrosis, Cancer, Sanford Burnham Prebys Medical Discovery Institute, Biology, Drug discovery, CEO, Drug resistance, Technology, Facebook, Health, Diabetes, Immunology, Patient, Institute, Autophagy, Laboratory, Genetics, Fibrosis, Salk Institute for Biological Studies, NCI, IND, Entrepreneurship, Alvin J. Siteman Cancer Center, Neoplasm, Disease, LKB1, Large-cell lung carcinoma, Cell biology, Ageing, Dream, KRAS, Biomedical Research, Recycling, Face, Nature, Lung, Research, Neuroscience, Oncogene, Pharmaceutical industry
Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, today announced the in-licensing of a ULK1/2 inhibitor program from the Salk Institute for Biological Studies and Sanford Burnham Prebys.
Key Points:
- Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, today announced the in-licensing of a ULK1/2 inhibitor program from the Salk Institute for Biological Studies and Sanford Burnham Prebys.
- Endeavor plans to complete IND-enabling studies and advance the program into the clinic initially in colorectal and lung cancers in the next 18 months.
- These patients are generally resistant to the standard of care (chemotherapy or immuno-oncology treatment) and face a very poor prognosis.
- Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis.